45781MAD3

Innoviva, Inc.

Could not find a ticker for this position, may be a filing error

A biopharmaceutical royalty company that developed respiratory medicines in partnership with GlaxoSmithKline, including the Ellipta inhaler products Breo and Anoro, and now earns ongoing royalties from those drugs. It was born in 2014 when the drug developer Theravance split in two: the research-and-development arm became Theravance Biopharma, while the royalty business took the name Innoviva. The name blends "innovation" and "vival"—a nod to the company's core role of keeping proven medicines alive in the market.

CONVERTIBLEUnderlying: INVACUSIP: 45781MAD3HealthcareUS1 derivative reporter

2.125% Convertible Senior Notes due 2028

Ownership Activity Financials Filings

45781MAD3

45781MAD3

Results of Operations and Financial Condition

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements

Results of Operations and Financial Condition

Submission of Matters to a Vote of Security Holders

Results of Operations and Financial Condition

Results of Operations and Financial Condition

Results of Operations and Financial Condition

Submission of Matters to a Vote of Security Holders